Mahana Therapeutics Enters Into Licensing Agreement With King’s College London for Innovative Digital Therapeutic to Treat Gastrointestinal Condition

Mahana Therapeutics is a digital therapeutics company reimagining the treatment of chronic diseases.  Today they announced that the Company has entered into a licensing and collaboration agreement with King’s College London, a leading research university and one of the oldest and most prestigious universities in England. Mahana has acquired a worldwide exclusive license to an innovative digital therapeutic for the treatment of irritable bowel syndrome (IBS).

Professor Rona Moss-Morris, Head of Psychology Department, Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London led the development of the digital program in collaboration with Trudie Chalder, Professor of Cognitive Behavioural Psychotherapy and Dr. Alice Sibelli both also from King’s, Hazel Everitt, GP and Professor of Primary Care Research, Faculty of Medicine, University of Southampton, and a broad multi-university team. “We spent over 18 years developing and clinically testing a personalized digital CBT program for adult IBS patients,” said Rona Moss Morris. “We believe our multi-center, randomized controlled trial (RCT) of 558 patients is the largest clinical trial ever conducted demonstrating the clinical safety and efficacy of a digital CBT product for IBS.” The trial, with results published in 2019 prestigious medical journal Gut[1], demonstrated that web-based CBT showed substantial and durable IBS symptom severity improvements versus treatment as usual (i.e. doctors visits alone) and also led to reductions in anxiety and depression in patients over three, six and twelve-month time periods.

“The digital era has allowed us the opportunity to explore new ways to reach patients and provide them with access to psychological-based therapies that help control symptoms in a more convenient way. We are thrilled to partner with Mahana Therapeutics. Mahana shares our vision to provide patients in the U.K. and abroad with clinically and cost-effective treatments for gastrointestinal diseases and they have been an amazing collaborative partner,” said Professor Moss-Morris.

“This is the perfect union of our vision at Mahana plus a leading academic institution’s desire to bring world-leading research into the hands of patients,” said Robert Paull, co-founder and CEO of Mahana Therapeutics. “The digital therapeutic developed by Professor Moss-Morris and her colleagues at King’s College London is best-in-class and supported by extensive clinical data. We are excited to bring this important treatment option to patients in the United Kingdom, United States and globally.


Reference

[1] Everitt HA, et al. Gut 2019;0:1–11. doi:10.1136/gutjnl-2018-317805

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version